Feeds:
Posts
Comments

Archive for the ‘Artificial Intelligence in Medicine – Applications in Therapeutics’ Category


Live Notes, Real Time Conference Coverage AACR 2020: Tuesday June 23, 2020 3:00 PM-5:30 PM Educational Sessions

Reporter: Stephen J. Williams, PhD

Follow Live in Real Time using

#AACR20

@pharma_BI

@AACR

Register for FREE at https://www.aacr.org/

uesday, June 23

3:00 PM – 5:00 PM EDT

Virtual Educational Session
Tumor Biology, Bioinformatics and Systems Biology

The Clinical Proteomic Tumor Analysis Consortium: Resources and Data Dissemination

This session will provide information regarding methodologic and computational aspects of proteogenomic analysis of tumor samples, particularly in the context of clinical trials. Availability of comprehensive proteomic and matching genomic data for tumor samples characterized by the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) and The Cancer Genome Atlas (TCGA) program will be described, including data access procedures and informatic tools under development. Recent advances on mass spectrometry-based targeted assays for inclusion in clinical trials will also be discussed.

Amanda G Paulovich, Shankha Satpathy, Meenakshi Anurag, Bing Zhang, Steven A Carr

Methods and tools for comprehensive proteogenomic characterization of bulk tumor to needle core biopsies

Shankha Satpathy
  • TCGA has 11,000 cancers with >20,000 somatic alterations but only 128 proteins as proteomics was still young field
  • CPTAC is NCI proteomic effort
  • Chemical labeling approach now method of choice for quantitative proteomics
  • Looked at ovarian and breast cancers: to measure PTM like phosphorylated the sample preparation is critical

 

Data access and informatics tools for proteogenomics analysis

Bing Zhang
  • Raw and processed data (raw MS data) with linked clinical data can be extracted in CPTAC
  • Python scripts are available for bioinformatic programming

 

Pathways to clinical translation of mass spectrometry-based assays

Meenakshi Anurag

·         Using kinase inhibitor pulldown (KIP) assay to identify unique kinome profiles

·         Found single strand break repair defects in endometrial luminal cases, especially with immune checkpoint prognostic tumors

·         Paper: JNCI 2019 analyzed 20,000 genes correlated with ET resistant in luminal B cases (selected for a list of 30 genes)

·         Validated in METABRIC dataset

·         KIP assay uses magnetic beads to pull out kinases to determine druggable kinases

·         Looked in xenografts and was able to pull out differential kinomes

·         Matched with PDX data so good clinical correlation

·         Were able to detect ESR1 fusion correlated with ER+ tumors

Tuesday, June 23

3:00 PM – 5:00 PM EDT

Virtual Educational Session
Survivorship

Artificial Intelligence and Machine Learning from Research to the Cancer Clinic

The adoption of omic technologies in the cancer clinic is giving rise to an increasing number of large-scale high-dimensional datasets recording multiple aspects of the disease. This creates the need for frameworks for translatable discovery and learning from such data. Like artificial intelligence (AI) and machine learning (ML) for the cancer lab, methods for the clinic need to (i) compare and integrate different data types; (ii) scale with data sizes; (iii) prove interpretable in terms of the known biology and batch effects underlying the data; and (iv) predict previously unknown experimentally verifiable mechanisms. Methods for the clinic, beyond the lab, also need to (v) produce accurate actionable recommendations; (vi) prove relevant to patient populations based upon small cohorts; and (vii) be validated in clinical trials. In this educational session we will present recent studies that demonstrate AI and ML translated to the cancer clinic, from prognosis and diagnosis to therapy.
NOTE: Dr. Fish’s talk is not eligible for CME credit to permit the free flow of information of the commercial interest employee participating.

Ron C. Anafi, Rick L. Stevens, Orly Alter, Guy Fish

Overview of AI approaches in cancer research and patient care

Rick L. Stevens
  • Deep learning is less likely to saturate as data increases
  • Deep learning attempts to learn multiple layers of information
  • The ultimate goal is prediction but this will be the greatest challenge for ML
  • ML models can integrate data validation and cross database validation
  • What limits the performance of cross validation is the internal noise of data (reproducibility)
  • Learning curves: not the more data but more reproducible data is important
  • Neural networks can outperform classical methods
  • Important to measure validation accuracy in training set. Class weighting can assist in development of data set for training set especially for unbalanced data sets

Discovering genome-scale predictors of survival and response to treatment with multi-tensor decompositions

Orly Alter
  • Finding patterns using SVD component analysis. Gene and SVD patterns match 1:1
  • Comparative spectral decompositions can be used for global datasets
  • Validation of CNV data using this strategy
  • Found Ras, Shh and Notch pathways with altered CNV in glioblastoma which correlated with prognosis
  • These predictors was significantly better than independent prognostic indicator like age of diagnosis

 

Identifying targets for cancer chronotherapy with unsupervised machine learning

Ron C. Anafi
  • Many clinicians have noticed that some patients do better when chemo is given at certain times of the day and felt there may be a circadian rhythm or chronotherapeutic effect with respect to side effects or with outcomes
  • ML used to determine if there is indeed this chronotherapy effect or can we use unstructured data to determine molecular rhythms?
  • Found a circadian transcription in human lung
  • Most dataset in cancer from one clinical trial so there might need to be more trials conducted to take into consideration circadian rhythms

Stratifying patients by live-cell biomarkers with random-forest decision trees

Stratifying patients by live-cell biomarkers with random-forest decision trees

Guy Fish CEO Cellanyx Diagnostics

 

Tuesday, June 23

3:00 PM – 5:00 PM EDT

Virtual Educational Session
Tumor Biology, Molecular and Cellular Biology/Genetics, Bioinformatics and Systems Biology, Prevention Research

The Wound Healing that Never Heals: The Tumor Microenvironment (TME) in Cancer Progression

This educational session focuses on the chronic wound healing, fibrosis, and cancer “triad.” It emphasizes the similarities and differences seen in these conditions and attempts to clarify why sustained fibrosis commonly supports tumorigenesis. Importance will be placed on cancer-associated fibroblasts (CAFs), vascularity, extracellular matrix (ECM), and chronic conditions like aging. Dr. Dvorak will provide an historical insight into the triad field focusing on the importance of vascular permeability. Dr. Stewart will explain how chronic inflammatory conditions, such as the aging tumor microenvironment (TME), drive cancer progression. The session will close with a review by Dr. Cukierman of the roles that CAFs and self-produced ECMs play in enabling the signaling reciprocity observed between fibrosis and cancer in solid epithelial cancers, such as pancreatic ductal adenocarcinoma.

Harold F Dvorak, Sheila A Stewart, Edna Cukierman

 

The importance of vascular permeability in tumor stroma generation and wound healing

Harold F Dvorak

Aging in the driver’s seat: Tumor progression and beyond

Sheila A Stewart

Why won’t CAFs stay normal?

Edna Cukierman

 

Tuesday, June 23

3:00 PM – 5:00 PM EDT

 

 

 

 

 

 

 

Other Articles on this Open Access  Online Journal on Cancer Conferences and Conference Coverage in Real Time Include

Press Coverage
Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Symposium: New Drugs on the Horizon Part 3 12:30-1:25 PM
Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Session on NCI Activities: COVID-19 and Cancer Research 5:20 PM
Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Session on Evaluating Cancer Genomics from Normal Tissues Through Metastatic Disease 3:50 PM
Live Notes, Real Time Conference Coverage 2020 AACR Virtual Meeting April 28, 2020 Session on Novel Targets and Therapies 2:35 PM

Read Full Post »


Powerful AI Tools Being Developed for the COVID-19 Fight

Curator: Stephen J. Williams, Ph.D.

 

Source: https://www.ibm.com/blogs/research/2020/04/ai-powered-technologies-accelerate-discovery-covid-19/

IBM Releases Novel AI-Powered Technologies to Help Health and Research Community Accelerate the Discovery of Medical Insights and Treatments for COVID-19

April 3, 2020 | Written by: 

IBM Research has been actively developing new cloud and AI-powered technologies that can help researchers across a variety of scientific disciplines accelerate the process of discovery. As the COVID-19 pandemic unfolds, we continue to ask how these technologies and our scientific knowledge can help in the global battle against coronavirus.

Today, we are making available multiple novel, free resources from across IBM to help healthcare researchers, doctors and scientists around the world accelerate COVID-19 drug discovery: from gathering insights, to applying the latest virus genomic information and identifying potential targets for treatments, to creating new drug molecule candidates.

Though some of the resources are still in exploratory stages, IBM is making them available to qualifying researchers at no charge to aid the international scientific investigation of COVID-19.

Today’s announcement follows our recent leadership in launching the U.S. COVID-19 High Performance Computing Consortium, which is harnessing massive computing power in the effort to help confront the coronavirus.

Streamlining the Search for Information

Healthcare agencies and governments around the world have quickly amassed medical and other relevant data about the pandemic. And, there are already vast troves of medical research that could prove relevant to COVID-19. Yet, as with any large volume of disparate data sources, it is difficult to efficiently aggregate and analyze that data in ways that can yield scientific insights.

To help researchers access structured and unstructured data quickly, we are offering a cloud-based AI research resource that has been trained on a corpus of thousands of scientific papers contained in the COVID-19 Open Research Dataset (CORD-19), prepared by the White House and a coalition of research groups, and licensed databases from the DrugBankClinicaltrials.gov and GenBank. This tool uses our advanced AI and allows researchers to pose specific queries to the collections of papers and to extract critical COVID-19 knowledge quickly. Please note, access to this resource will be granted only to qualified researchers. To learn more and request access, please click here.

Aiding the Hunt for Treatments

The traditional drug discovery pipeline relies on a library of compounds that are screened, improved, and tested to determine safety and efficacy. In dealing with new pathogens such as SARS-CoV-2, there is the potential to enhance the compound libraries with additional novel compounds. To help address this need, IBM Research has recently created a new, AI-generative framework which can rapidly identify novel peptides, proteins, drug candidates and materials.

We have applied this AI technology against three COVID-19 targets to identify 3,000 new small molecules as potential COVID-19 therapeutic candidates. IBM is releasing these molecules under an open license, and researchers can study them via a new interactive molecular explorer tool to understand their characteristics and relationship to COVID-19 and identify candidates that might have desirable properties to be further pursued in drug development.

To streamline efforts to identify new treatments for COVID-19, we are also making the IBM Functional Genomics Platform available for free for the duration of the pandemic. Built to discover the molecular features in viral and bacterial genomes, this cloud-based repository and research tool includes genes, proteins and other molecular targets from sequenced viral and bacterial organisms in one place with connections pre-computed to help accelerate discovery of molecular targets required for drug design, test development and treatment.

Select IBM collaborators from government agencies, academic institutions and other organizations already use this platform for bacterial genomic study. And now, those working on COVID-19 can request the IBM Functional Genomics Platform interface to explore the genomic features of the virus. Access to the IBM Functional Genomics Platform will be prioritized for those conducting COVID-19 research. To learn more and request access, please click here.

Drug and Disease Information

Clinicians and healthcare professionals on the frontlines of care will also have free access to hundreds of pieces of evidence-based, curated COVID-19 and infectious disease content from IBM Micromedex and EBSCO DynaMed. Using these two rich decision support solutions, users will have access to drug and disease information in a single and comprehensive search. Clinicians can also provide patients with consumer-friendly patient education handouts with relevant, actionable medical information. IBM Micromedex is one of the largest online reference databases for medication information and is used by more than 4,500 hospitals and health systems worldwide. EBSCO DynaMed provides peer-reviewed clinical content, including systematic literature reviews in 28 specialties for comprehensive disease topics, health conditions and abnormal findings, to highly focused topics on evaluation, differential diagnosis and management.

The scientific community is working hard to make important new discoveries relevant to the treatment of COVID-19, and we’re hopeful that releasing these novel tools will help accelerate this global effort. This work also outlines our long-term vision for the future of accelerated discovery, where multi-disciplinary scientists and clinicians work together to rapidly and effectively create next generation therapeutics, aided by novel AI-powered technologies.

Learn more about IBM’s response to COVID-19: IBM.com/COVID19.

Source: https://www.ibm.com/blogs/research/2020/04/ai-powered-technologies-accelerate-discovery-covid-19/

DiA Imaging Analysis Receives Grant to Accelerate Global Access to its AI Ultrasound Solutions in the Fight Against COVID-19

Source: https://www.grantnews.com/news-articles/?rkey=20200512UN05506&filter=12337

Grant will allow company to accelerate access to its AI solutions and use of ultrasound in COVID-19 emergency settings

TEL AVIV, IsraelMay 12, 2020 /PRNewswire-PRWeb/ — DiA Imaging Analysis, a leading provider of AI based ultrasound analysis solutions, today announced that it has received a government grant from the Israel Innovation Authority (IIA) to develop solutions for ultrasound imaging analysis of COVID-19 patients using Artificial Intelligence (AI).Using ultrasound in point of care emergency settings has gained momentum since the outbreak of COVID-19 pandemic. In these settings, which include makeshift hospital COVID-19 departments and triage “tents,” portable ultrasound offers clinicians diagnostic decision support, with the added advantage of being easier to disinfect and eliminating the need to transport patients from one room to another.However, analyzing ultrasound images is a process that it is still mostly done visually, leading to a growing market need for automated solutions and decision support.As the leading provider of AI solutions for ultrasound analysis and backed by Connecticut Innovations, DiA makes ultrasound analysis smarter and accessible to both new and expert ultrasound users with various levels of experience. The company’s flagship LVivo Cardio Toolbox for AI-based cardiac ultrasound analysis enables clinicians to automatically generate objective clinical analysis, with increased accuracy and efficiency to support decisions about patient treatment and care.

The IIA grant provides a budget of millions NIS to increase access to DiA’s solutions for users in Israel and globally, and accelerate R&D with a focus on new AI solutions for COVID-19 patient management. DiA solutions are vendor-neutral and platform agnostic, as well as powered to run in low processing, mobile environments like handheld ultrasound.Recent data highlights the importance of looking at the heart during the progression of COVID-19, with one study citing 20% of patients hospitalized with COVID-19 showing signs of heart damage and increased mortality rates in those patients. DiA’s LVivo cardiac analysis solutions automatically generate objective, quantified cardiac ultrasound results to enable point-of-care clinicians to assess cardiac function on the spot, near patients’ bedside.

According to Dr. Ami Applebaum, the Chairman of the Board of the IIA, “The purpose of IIA’s call was to bring solutions to global markets for fighting COVID-19, with an emphasis on relevancy, fast time to market and collaborations promising continuity of the Israeli economy. DiA meets these requirements with AI innovation for ultrasound.”DiA has received several FDA/CE clearances and established distribution partnerships with industry leading companies including GE Healthcare, IBM Watson and Konica Minolta, currently serving thousands of end users worldwide.”We see growing use of ultrasound in point of care settings, and an urgent need for automated, objective solutions that provide decision support in real time,” said Hila Goldman-Aslan, CEO and Co-founder of DiA Imaging Analysis, “Our AI solutions meet this need by immediately helping clinicians on the frontlines to quickly and easily assess COVID-19 patients’ hearts to help guide care delivery.”

About DiA Imaging Analysis:
DiA Imaging Analysis provides advanced AI-based ultrasound analysis technology that makes ultrasound accessible to all. DiA’s automated tools deliver fast and accurate clinical indications to support the decision-making process and offer better patient care. DiA’s AI-based technology uses advanced pattern recognition and machine-learning algorithms to automatically imitate the way the human eye detects image borders and identifies motion. Using DiA’s tools provides automated and objective AI tools, helps reduce variability among users, and increases efficiency. It allows clinicians with various levels of experience to quickly and easily analyze ultrasound images.

For additional information, please visit http://www.dia-analysis.com.

Read Full Post »


2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Dialogue among principals is a World Forum’s signature. Expert moderators guiding discussion and questions in audience friendly exchanges. No slides – shared perspectives facilitated by Harvard faculty, leading journalists and Mass General Brigham executives.

Jeffrey Golden, MD

Chair, Department of Pathology, BH; Ramzi S. Cotran Professor of Pathology, Harvard Medical School

Hadine Joffe, MD

Vice Chair, Psychiatry, Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology, BH; Paula A. Johnson Professor, Women’s Health, Harvard Medical School

Thomas Sequist, MD

Chief Patient Experience and Equity Officer, Mass General Brigham; Professor of Medicine and Health Care Policy, Harvard Medical School

Erica Shenoy, MD, PhD

Associate Chief, Infection Control Unit, MGH; Assistant Professor, Harvard Medical School

Gregg Meyer, MD

Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor, Harvard Medical School

Ravi Thadhani, MD

CAO, Mass General Brigham; Professor and Faculty Dean for Academic Programs, Harvard Medical School

Ann Prestipino

SVP; Incident Commander, MGH

Roger Kitterman

VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham

David Louis, MD

Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, Harvard Medical School

Janet Wu

Bloomberg

Ron Walls, MD

EVP and Chief Operating Officer, BH; Neskey Family Professor of Emergency Medicine, Harvard Medical School

Alice Park

Senior Writer, TIME

 

Jeffrey Golden, MD

Chair, Department of Pathology, BH; Ramzi S. Cotran Professor of Pathology, Harvard Medical School

Hadine Joffe, MD

Vice Chair, Psychiatry, Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology, BH; Paula A. Johnson Professor, Women’s Health, Harvard Medical School

Thomas Sequist, MD

Chief Patient Experience and Equity Officer, Mass General Brigham; Professor of Medicine and Health Care Policy, Harvard Medical School

Erica Shenoy, MD, PhD

Associate Chief, Infection Control Unit, MGH; Assistant Professor, Harvard Medical School

Gregg Meyer, MD

Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor, Harvard Medical School

Ravi Thadhani, MD

CAO, Mass General Brigham; Professor and Faculty Dean for Academic Programs, Harvard Medical School

Ann Prestipino

SVP; Incident Commander, MGH

Roger Kitterman

VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham

David Louis, MD

Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, Harvard Medical School

Janet Wu

Bloomberg

Ron Walls, MD

EVP and Chief Operating Officer, BH; Neskey Family Professor of Emergency Medicine, Harvard Medical School

Alice Park

Senior Writer, TIME

 

VIEW VIDEOS from the event

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

 

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum  

 

Dear World Forum Attendee, 

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that  will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators.  As promised, we  wanted to also share visual Forum session summaries.  You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!  

Thanks again, Chris

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/05/11/tweets-retweets-2020-world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-mond/

Read Full Post »


Collaborative innovation has never been more important.

2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

Join top leaders guiding the response, technology and people confronting this century’s greatest health challenge.

Priya Abani

CEO, AliveCor

General Keith Alexander

Co-CEO, IronNet; Former NSA Head

Stéphane Bancel

CEO, Moderna

Marc Casper

CEO, Thermo Fisher

Timothy Ferris, MD

CEO, MGPO; Professor, HMS

John Fernandez  

President, MEE; President, Ambulatory Care, Mass General Brigham

 

John Fish

CEO, Suffolk; BH Board Chair

JF Formela, MD

Partner, Atlas Venture

Jan Garfinkle

Manager Partner, Arboretum Ventures; Chair, NVCA

Phillip Gross

Managing Director, Adage Capital Management

Julia Hu

CEO, Lark Health

Anjali Kataria

CEO, Mytonomy

Roger Kitterman

VP, Managing Partner, Mass General Brigahm Fund

Jonathan Kraft

President, Kraft Group; Chair, MGH Board

Brooke LeVasseur

CEO, AristaMD

Mike Mahoney

CEO, Boston Scientific

Bernd Montag, PhD

CEO, Siemens Healthineers

Kieran Murphy

CEO, GE Healthcare

Elizabeth Nabel, MD

President, BH; Professor, HMS

Matt Sause

CEO, Roche Diagnostics

Peter Slavin, MD

President, MGH; Professor, HMS

Scott Sperling

Co-President, TH Lee; Chair, Mass General Brigham Board

Christopher Viehbacher

Managing Partner, Gurnet Point Capital

Michel Vounatsos

CEO, Biogen

Collaborative Innovation

Together we meet the challenge of the coronavirus and share our commitment to the future of medicine.

 

Anne Klibanski, MD

CEO, Mass General Brigham

Amy Abernethy, MD, PhD

Principal Deputy Commissioner and Acting CIO, FDA

PANEL

FDA Role in Managing Crisis and Anticipating the Next

Elizabeth Nabel, MD

President, Brigham Health; Professor of Medicine, HMS

PANEL

Care in the Next 18 Months 

Karen DeSalvo, MD

Chief Health Officer, Google Health

PANEL

Role of AI and Big Data in Fighting COVID-19 

Dawn Sugarman, PhD

Assistant Psychologist, Division of Alcohol, Drugs, and Addiction, McLean; Assistant Professor, Psychiatry, HMS

PANEL

Digital Therapeutics

Ann Prestipino

SVP; Incident Commander, MGH; Teaching Associate, HMS

PANEL

Real Time: Front Line Innovation

Hadine Joffe, MD

Vice Chair, Research, Psychiatry; Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology, BH; Paula Johnson Professor, Women’s Health, HMS

PANEL

Digital Therapeutics

Priya Abani

CEO, AliveCor

PANEL

Digital Therapeutics

Julia Hu

CEO, Lark Health

PANEL

Digital Therapeutics

Jan Garfinkle

Manager Partner, Arboretum Ventures; Chair NVCA

PANEL

Early Stage Investment Environment

Anjali Kataria

CEO, Mytonomy

PANEL

Patient Experience During the Pandemic

Brooke LeVasseur

CEO, AristaMD

PANEL

Digital Health Becomes a Pillar

Julie Lankiewicz

Head, Clinical Affairs & Health Economics Outcomes Research, Bose Health

PANEL

Emergency and Urgent Care

 

VIEW VIDEOS from the event

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

 

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum  

 

Dear World Forum Attendee, 

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that  will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators.  As promised, we  wanted to also share visual Forum session summaries.  You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!  

Thanks again, Chris

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/05/11/tweets-retweets-2020-world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-mond/

Read Full Post »


2020 World Medical Innovation Forum – COVID-19, AI  – Life Science and Digital Health Investments, MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

 

 

 

Life science and digital health investments have continued at a strong pace during the COVID-19 crisis. Senior investment leaders discuss what to expect. Will:

  • social distancing affect deal making?
  • key asset categories remain strong – venture, private equity, public offerings, acquisitions?
  • valuations hold up in some categories while others fall?

Moderator: Roger Kitterman, VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham


Jan Garfinkle
, Founder & Manager Partner, Arboretum Ventures, Chair NVCA

Phillip Gross, Managing Director, Adage Capital Management

Christopher Viehbacher, Managing Partner, Gurnet Point Capital

 

VIEW VIDEOS from the event

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum  

 

Dear World Forum Attendee, 

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that  will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators.  As promised, we  wanted to also share visual Forum session summaries.  You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!  

Thanks again, Chris

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/05/11/tweets-retweets-2020-world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-mond/

Read Full Post »


Tweets & Retweets 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

From: “Partners Innovation (via Twitter)” <notify@twitter.com>

Date: Tuesday, May 12, 2020 at 2:24 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Partners Innovation (@PHSInnovation) has sent you a Direct Message on Twitter!

 

Thanks for tweeting about the live event Aviva! We appreciate the support!

 

e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

https://pharmaceuticalintelligence.com/2020/04/22/world-medical-innovation-forum-covid-19-ai-and-the-future-of-medicine-featuring-harvard-and-industry-leader-insights-mgh-bwh-virtual-event-monday-may-11-815-a-m-515-p-m-et/

VIEW ALL VIDEOS

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

 

Aviva Lev-Ari
@AVIVA1950

#WMIF2020

Michel Vounatsos, CEO, Biogen Venture community supportive to be on the safe side  employees tested every evenings to prevent rebound of the pandemic Pandemic is acceleration progress technologies new drugs Biogen will lead new model

Notifications

#WMIF2020 @PHSInnovation @pharma_BI @AVIVA1950 Digital Therapeutics Hadine Joffe, MD @BH; Paula A. Johnson Professor, Women’s Health, HMS Priya Abani, CEO, AliveCor Julia Hu, CEO, Lark Health Dawn Sugarman, PhD @McLeanHospital

liked your Tweet

#WMIF2020 @PHSInnovation @pharma_BI @AVIVA1950 Joerg Moeller, MD, PhD, Head of Research @BayerPharmaAG led team of 9 products Unprecedented is COVID-19: effect on work, travel, lifevAnti-Malaria vs COVID-19: In China testing early chloroquine approved for RA and anti Malaria

Retweeted 78 of your Tweets

#WMIF2020 @PHSInnovation @pharma_BI @AVIVA1950 Michael Mina, MD, PhD @BH Antigen test for home administration consumerization of the Testing  Walmart can be positioned for blood tests Not only Physicians can order tests @Microsoft @Amazon can interpretation of Test using Alexa

Show all

liked 85 of your Tweets

#WMIF2020 @PHSInnovation @pharma_BI @AVIVA1950 Michael Mina, MD, PhD @BH Antigen test for home administration consumerization of the Testing  Walmart can be positioned for blood tests Not only Physicians can order tests @Microsoft @Amazon can interpretation of Test using Alexa

Show all

Stephen J Williams
@StephenJWillia2

Quote Tweet
Aviva Lev-Ari
@AVIVA1950
·
#WMIF2020 @PHSInnovation @pharma_BI @AVIVA1950 Ross Zafonte, DO, SVP, Research Education and Medical Affairs, SRN; Earle P. and Ida S. Charlton Professor of Physical Medicine and Rehabilitation, HMS @MGH is family, the unattainable is attainable

Stephen J Williams
@StephenJWillia2

#WMIF2020 #Telemedicine so important for #COVID19 pandemic. Platforms developed years ago. Who would have known?

Quote Tweet
Aviva Lev-Ari
@AVIVA1950
·
#WMIF2020 @PHSInnovation @pharma_BI @AVIVA1950 Jan Garfinkle, Founder & Manager Partner, Arboretum Ventures Can you close a deal with out meeting management team Known funds will prevail vs new funds Parma adjacencies vs medical devices Telehealth is of interest GI Cardiovascular

Stephen J Williams
@StephenJWillia2

Quote Tweet
Aviva Lev-Ari
@AVIVA1950
·
#WMIF2020 @PHSInnovation @pharma_BI @AVIVA1950 Ravi Thadhani, MD, CAO, Mass General Brigham; Professor of Medicine and Faculty Dean for Academic Programs, HMS Great Broadcasting services, expertise on the top Management of the Event 100% no room to improve Recovery COVID Patients

Stephen J Williams
@StephenJWillia2

2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – #MGH & #BWH Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET #WMIF

#bostonbio pharmaceuticalintelligence.com/2020/04/22/wor via

2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard…
2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. –…
pharmaceuticalintelligence.com
1
1
News for you
Fears of homophobic backlash sparked as Korean media focus on gay club COVID-19 case

Retweeted your Tweet

#WMIF20 @pharma_BI @AVIVA1950 covering event in #realtime +9,500 Global Attendees for lnkd.in/ePwTDxm about worldmedicalinnovation.org/2020-disruptiv 2020 #Virtual #World #Medical #Innovation #Forum#COVID-19 #AI #Future #Medicine @MGH & @BWH, Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

liked your Tweet

#WMIF20 @pharma_BI @AVIVA1950 covering event in #realtime +9,500 Global Attendees for lnkd.in/ePwTDxm about worldmedicalinnovation.org/2020-disruptiv 2020 #Virtual #World #Medical #Innovation #Forum#COVID-19 #AI #Future #Medicine @MGH & @BWH, Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

All Tweets by @AVIVA1950 on May 11, 2020

Read Full Post »


e-Proceedings 2020 World Medical Innovation Forum – COVID-19, AI and the Future of Medicine, Featuring Harvard and Industry Leader Insights – MGH & BWH, Virtual Event: Monday, May 11, 8:15 a.m. – 5:15 p.m. ET

 

Featuring Clinical, Scientific, Tech, AI and Venture Experts

https://worldmedicalinnovation.org/

7:50NOW PLAYING

2020 WMIF | Welcome

34 views1 hour ago

5:31NOW PLAYING

2020 WMIF | Disruptive Dozen #1

122 views1 day ago

3:27NOW PLAYING

3:56NOW PLAYING

2020 WMIF | Disruptive Dozen #4

57 views2 days ago

SOURCE

https://www.youtube.com/channel/UCauKpbsS_hUqQaPp8EVGYOg

 

THIS IS THE EVENT I COVERED on 5/11/2020  BY INVITATION AS MEDIA for Mass General Brigham

 

From: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Date: Tuesday, May 12, 2020 at 6:48 AM

To: “Coburn, Christopher Mark” <CMCOBURN@PARTNERS.ORG>

Subject: REGISTRANT RECAP | World Medical Innovation Forum  

 

Dear World Forum Attendee, 

On behalf of Mass General Brigham CEO Anne Klibanski MD and Forum co-Chairs Gregg Meyer MD and Ravi Thadhani MD, many thanks for being among the nearly 11,000 registrants representing 93 countries, 46 states and 3200 organizations yesterday. A community was established around many pressing topics that  will continue long into the future. We hope you have a chance to examine the attached survey results. There are several revealing items that should be the basis for ongoing discussion. We expect to be in touch regularly during the year. Among the plans is a “First Look” video series highlighting top Mass General Brigham Harvard faculty as well as emerging Harvard investigators.  As promised, we  wanted to also share visual Forum session summaries.  You will be able to access the recordings on the Forum’s YouTube page . The first set will go up this morning

We hope you will join us for the 2021 Forum!  

Thanks again, Chris

 

Mass General Brigham (formerly Partners Healthcare) is pleased to invite media to attend the World Medical Innovation Forum (WMIF) virtual event on Monday, May 11. Our day-long interactive web event features expert discussions of COVID-related infectious disease innovation and the pandemic’s impact on transforming medicine, plus insights on how care may be radically transformed post-COVID. The agenda features nearly 70 executive speakers from the healthcare industry, venture, start-ups, consumer health and the front lines of COVID care, including many of our Harvard Medical School-affiliated researchers and clinicians. The event replaces our annual in-person conference, which we plan to resume in 2021.

 

Aviva Lev-Ari, PhD, RN, Editor-in Chief, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston will cover the event in Real Time as MEDIA for our Coronavirus Portal

CORONAVIRUS, SARS-CoV-2 PORTAL @LPBI

http://lnkd.in/ePwTDxm

Launched on 3/14/2020

8:15 – 8:25 AM
Opening Remarks

Dr. Klibanski will welcome participants to the 2020 World Medical Innovation Forum, a global — and this year, virtual — gathering of more than 5,000 senior health care leaders. This annual event was established to respond to the intensifying transformation of health care and its impact on innovation. The Forum is rooted in the belief that no matter the magnitude of that change, the center of health care needs to be a shared, fundamental commitment to collaborative innovation – industry and academia working together to improve patient lives. No collaborative endeavor is more pressing than responding to the COVID-19 pandemic.

Introduction:
Scott Sperling, Co-President, Thomas H. Lee Partners; Chairman of the Board of Directors, Mass General Brigham

  • Introducing Anne Klibanski – Leadership at its best for breakthroughs in the entire system when return to normalcy

Anne Klibanski, MD, President & CEO, Mass General Brigham

  • Collaborative innovation between Industry and Hospitals and Government
  • Expediting innovations: Prophylactic, Diagnostics, research and care delivery
  • COVID caregivers contribution to this battle, patient experience and outcome

Add Panel to Calendar

8:25 – 8:50 AM
Care in the Next 18 Months – Routine, Elective, Remote

Hospital chief executives reflect on how health care will evolve over the next 18 months in the face of COVID-19. What will routine health care look like? What about elective surgeries and other interventions? And will care-at-a-distance continue to be an essential component? Simply put, how will we provide manage, and pay for health care in a world forever changed by COVID-19?

Moderator:
Gregg Meyer, MD, Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor of Medicine, HMS

John Fernandez,  President, Mass Eye and Ear and Mass General Brigham Ambulatory Care

  • Out patients decrease in volume now social distancing enabled by using parking lot as waiting rooms
  • Pre visit and post visit websites will become places of touch – patients accessing via website

Elizabeth Nabel, MD, President, Brigham Health; Professor of Medicine, HMS

  • Support to frontline care
  • Old normal will not be the new normal
  • Telehealth and digital health, work force, healthcare experience, improve access
  • lower medical expense
  • Patients were afraid
  • deferred cancer operation and treatment
  • Cath Lab less 50% occupied
  • Hospitals are safe and patients must come back for procedures
  • COVID-19 only 20% of all patients
  • ICU and OR Scheduling rethink procedure digital care delivers procedures
  • deploy workforce work across repurposed units hybrids, talent acquisition new strategy
  • COVID-19 will have distinct areas
  • BWH – Patient-Nurse-Doctor relations in healing Healthcare team became the Family of the Patients

Peter Slavin, MD, President, MGH; Professor, Health Care Policy, HMS

  • Reemerging more complicated
  • In patients and Out patient realigned with care for COVID-19
  • Telemedicine 85% of outpatients visits at MGH
  • virtual care will dominate the future of care
  • disadvantaged populations suffered more in the pandemic Communities in Chelsea and Revere household received kits social determinants of illness

Add Panel to Calendar

8:50 – 9:15 AM
COVID-19: Technology Solutions Now and in the Future

Experts leading large teams at the epicenter of the coronavirus outbreak discuss how technology is shaping the pandemic response today and in the coming years. What technology categories are most important? What tools are healthcare organizations, biopharmaceutical companies, and other organizations leveraging to battle this crisis? How will those tools evolve? And, importantly, how can technology inform the medical response to future pandemics? What were the biggest technology surprises in the current response?

Moderator:
Alice Park, Senior Writer, Time

Stephane Bancel, CEO, Moderna

  • mRNA synthetic RNA of Spike protein injected to stir immune response
  • Phase II working with FDA starting Phase III early Summer
  • 15 mcg dose available in 2020
  • using own capital to invest to scale up manufacturing no help from Gov’t Grant for clinical trial not for manufacturing

Paul Biddinger, MD, Medical Director for Emergency Preparedness, MGH; Associate Professor of Emergency Medicine, HMS

  • Sharing information across the system aggregate data technologies
  • ML as Guidance in resource coordination

David Kaufman, MD, PhD, Head of Translational Development, Bill & Melinda Gates Medical Research Institute

  • drug development, clinical operations remote monitoring
  • repurpose compounds usinf libraries
  • scalability and Global vaccine cheap and available globally
  • complexity is in coordinations – toolset  biology tool RNA mapping viral screening primaru cells and organoids
  • Outcomes: Aging and co-morbidities
  • Discovery effort using tools infrastructure maintained between pandemics

Rochelle Walensky, MDChief, Infectious Disease, Steve and Deborah Gorlin MGH Research Scholar, MGH; Professor of Medicine, HMS

  • shared photos important for Public health, using iPhone distribution Demedicalize Testic – not only at clinics but at many placed contact tracing and diagnosis in 24 hours – iPhone is invaluable GPS capability – privacy issues
  • detect patients with high risk and existing infection monitoring
  • Public Health – Thermometer given to Patients – data collected centrally any spike and pulse oximeter given to home – remote
  • Anxiety in opening the economy requires a bit of giving up on privacy
  • TeleHealth and monitoring remotely
  • Pharmacy and workplace as points to start Testing vs Order and a nurse call

Add Panel to Calendar

9:15 – 9:40 AM
Digital Health Becomes a Pillar: Tools, Payment, Data

Deployed in the crucible of the coronavirus pandemic, digital health has now become an essential pillar in the delivery of care. Why is that significant? How and why did it happen? What are the essential tools and components? How is the electronic health record and other health data contributing to this digital movement?

Are there novel use cases for telehealth that arose during the first phase of the COVID-19 pandemic? How can digital technologies help enable a full return to work. Thinking ahead to the fall and a possible second wave, are there things we should be doing today to ensure this technology to better detect and profile a resurgence and enhance the patient benefit.

Moderator:
David Louis, MD, Pathologist-in-Chief, MGH; Benjamin Castleman Professor of Pathology, HMS

  • DIgitsl technologies – boostong and innovating
  • upscale activity
  • risk of upscaling on Providers
  • Adaptations of innovation

Alistair Erskine, MD, Chief Digital Health Officer, Mass General Brigham

Adam Landman, MD, VP, Chief Information and Digital Innovation Officer, BH; Associate Professor of Emergency Medicine, HMS

  • COVID-19 call center across Partners, Chat bots automated screening tools, Microsoft assisted 60,000 users of chat bots triaging by screening calls of the Hotline
  • TeleHealth transformation may be lost due to reimbursement which may not be reimburse after the emergency is over Insurers to incentivize use of of TeleHealth
  • In person care: Redesign and how to provide In care for the staff and for the Patients

Brooke LeVasseur, CEO, AristaMD

  • Access problem due to care shortage of specialty care
  • technology better allocate resources
  • Industry and Hospital Institutions populations they serve
  • innovations needs a sustainable economic model for reimbursement
  • Inequity issues How Telehealth can benefit all of Society, potential for future solutions

Lee Schwamm, MD, Director, Center for TeleHealth and Exec Vice Chair, Neurology, MGH; Vice President, Virtual Care/Digital Health, Mass General Brigham; Professor, Neurology, HMS

  • Surge capabilities
  • generate insight
  • Research and Innovation needs embedding in the enterprise
  • technical gap in maintenance
  • supply chain disrupted

Add Panel to Calendar

9:40 – 9:45 AM
BREAK
9:45 – 10:05 AM
FIRESIDE CHAT
Bayer Pharma Reflections on Innovation: Creating, Collaborating, and Accelerating Discovery During and After a Pandemic

Dr. Moeller will reflect on how Bayer is weathering the organizational challenges posed by the COVID-19 pandemic. How does a global pharmaceutical company continue to drive drug development when its labs are shut down? What are the critical elements needed to keep the engines of innovation firing even in the face of a global public health crisis? How does a global r&d enterprise plan for an uncertain fall 2020 given a potential return of the virus.

Introduction:
John Fish, CEO, Suffolk; Chairman of Board Trustees, Brigham Health

  • COPD

Moderator:
Janet Wu, Bloomberg

Joerg Moeller, MD, PhD, Head of Research & Development, Pharmaceuticals Division, Bayer AG

  • led team of 9 products
  • Unprecedented is COVID-19: effect on work, travel, life
  • Anti-Malaria vs COVID-19: In China testing early chloroquine approved for RA and anti Malaria Government in China experimental and Bayer supports Clinical Trials by Bill & Melinda Foundation
  • In 8 weeks most Scientist work from home – amazed what was accomplished by 80% of Bayer working from home
  • production is kept ongoing anti-infective for Pneumonia
  • focus on most critical and keep experiment critical and push out studies run Globally – No pre-maturely study was interrupted completely
  • Great collaboration Flexibility with regulatory agencies in Europe and with FDA – levels not seen before
  • R&D in Pharma – when out different point than when we started: Opportunities- Compound libraries OPEN after the COVID Pandemic, speed of decision making, team spirit outstanding – levels not seen before
  • Partnerships: Bayer testing machines and ventilators shared, accelerate mechanisms for new drug development
  • evidence for repurposing drugs: Chloroquine
  • Solidarity – everyone are in it TOGETHER, keep that after the Pandemic is over – levels not seen before

Add Panel to Calendar

10:05 – 10:30 AM
The Patient Experience During the Pandemic

The coronavirus outbreak is not only testing health care staff and resources, it is also having an overwhelming impact on patients. This panel will focus on the approach and technologies providers are using to address the patient experience along the continuum of care.

Moderator:
Thomas Sequist, MD, Chief Patient Experience and Equity Officer, Mass General Brigham; Professor of Medicine and Health Care Policy, HMS

Anjali Kataria, CEO, Mytonomy

  • Video overcome illiteracy and provide personal engagement without the negative
  • Home health will be the shift – a human component will not go away – sensor technology in car, bathroom
  • COVID-19 accelerated user adoption of Telehealth
  • Digital technologies as an equailizer Hispanic patients consumed for information with the new technologies

Daniel Kuritzkes, MD, Chief, Division of Infectious Diseases, BH; Harriet Ryan Albee Professor of Medicine, HMS

  • conserve PPE impacted Physicians ability to see Patients, Nurses meet patients vs Physicians that delivered care remotely – laying on hands was missing in the care
  • Masks will not come off but in a while, can’t allow the infection to surge and curtail hospitals from functioning, use mask for the foreseable future

 

Peter Lee, PhD, Corporate Vice President, Microsoft Research and Incubation

  • Interactive Chat bots 1 out of 500 hospitals around the Globe adopted the Chat Bot for Patient Intake
  • Scaling telemetry with feedback loop
  • iPad at bedside, platform orchestration, new workflows for COVID-19 patients in the backend guiding Patients in the Process was new infrastructure was in the front line
  • preparing for a game change in Medicine: Patients demanding new experience
  • Historical context for physicians contribution to care and bridge the digital divide

Jag Singh, MD, PhD, Cardiologist & Founding Director, Resynchronization and Advanced Cardiac Therapeutics Program, MGH; Professor of Medicine, HMS

  • Isolation is unbearable
  • Predictive analytics
  • no going back to before Pandemic
  • COVID-19 only severe go to hospital
  • Human contact enhanced interaction with families and Docs

Add Panel to Calendar

10:30 – 10:55 AM
The Role of AI and Big Data in Fighting COVID-19 and the Next Global Crisis – Successes and Aspirations

AI is a key weapon used to fight COVID-19. What are the biggest successes so far? Which applications show the most promise for the future? Can it help a return to work? Can AI help predict and even prevent the next global health care crisis?

Moderator:
Alice Park, Senior Writer, Time

Mike Devoy, MD, EVP, Medical Affairs & Pharmacovigilance and CMO, Bayer AG

  • AI allows speeding up Genome of Spike Proteins sequencing
  • Partnership with Academia help focus effort
  • openness and willingness to collaborate and take risk in Therapeutics

Karen DeSalvo, MD,  Chief Health Officer, Google Health

  • Partnership with Apple on Contact Tracing System – BLE – only for Health applications
  • Public Health as driver as consumer Privacy preserving
  • Individual level data collection for AI applications, privacy giving up for public good
  • Trust component – in sharing data

Keith Dreyer, DO, PhD, Chief Data Science Officer, Mass General Brigham; Vice Chairman, Radiology, MGH; Associate Professor, Radiology, HMS

  • COVID allowed data on contact tracing
  • AI in image capturing for Public health – target Imaging use data to be equivalent to Human Testing at Home va in ER 1 in 10, 000 vs all populations
  • Data to AI application SW providers are stewards Open source , no conflict of interest and no discussion on profits
  • Each country will have own lessens

Add Panel to Calendar

10:55 – 11:20 AM
Designing for Infection Prevention: Innovation and Investment in Personal Protective Equipment and Facility Design

As with many pathogens, prevention is the best defense against SARS-CoV2, the virus that causes COVID-19. Panelists will discuss the insights, design strategies, technologies, and practices that are emerging to guard against infection and how those innovations are being applied to protect health care providers and their patients.
Based on what was learned during the spring of 2020, are there specific changes that will lessen morbidity and mortality in a potential a second wave?

Moderator:
Erica Shenoy, MD, PhD, Associate Chief, Infection Control Unit, MGH; Assistant Professor, HMS

Shelly AndersonSVP, Strategic Initiatives and Partnerships, & Chief Strategy Officer, BH

  • How to establish the New normal
  • Surveillence for new sources of infection
  • Operations under uncertainty
  • learned to be effective with data monitoring, training, facility adaptation to new roles
  • Investments in new materials to stabilize the supply chain: Additional suppliers,
  • Extend internal supply work with R&D on alternative materials

Michele Holcomb, PhD, EVP, Strategy and Corporate Development, Cardinal Health

  • Optimize toward lower cost vs availability of supply
  • Diverting supply chain to manufacturing not in PPE business

 

Guillermo Tearney, MD, PhD, Remondi Family Endowed MGH Research Institute Chair, Mike and Sue Hazard MGH Research Scholar, MGH; Professor, Pathology, HMS

  • 3D Printing innovations for filtration capacity of particles, respirators decontaminated, prevention of patient transmission
  • Negative pressure applied on materials as second line of protection beyond PPE
  • CPAP to be used
  • weaning from Ventilators to CPAP
  • Environment to be protected from air born pathogens

Teresa Wilson, Director/Architect, Colliers Project Leaders

  • Physical Design of the facility and rooms – use design to minimize Hospital infections principals of location of clean vs dirty functions
  • room kept cleaned, how long it takes to clean, where is the sink, hands free, modular construction plug & play design of rooms functions

Add Panel to Calendar

11:20 – 11:25 AM
BREAK
11:25 – 11:45 AM
FIRESIDE CHAT
Preparing for Fall 2020 and Beyond: Production, Innovation, Optimization

How does a global medical technology and life sciences company respond to the health challenges posed by COVID-19? Mr. Murphy will reflect on how his organization is working to meet the unprecedented demand for life-saving medical equipment for diagnosing, treating, and managing coronavirus patients. How does a large manufacturer make adjustments to FDA regulated products and supply chains in time to help lessen the impact of a second wave of COVID-19 infections.

Introduction:
Jonathan Kraft, President, The Kraft Group; Chair, Mass General Hospital Board of Trustees

  • 90 countries around the Globe – collaborative innovations partnership with GE Health – all assets around the World
  • Academic with GE Health AI, Diagnostics, data set for ML for Health care

Moderator:
Timothy Ferris, MD, CEO, MGPO; Professor, HMS

Kieran Murphy, CEO, GE Healthcare

  • Partnership GE Health & MGH
  • COVID-19 Innovations and Customers needs: Ventilators and
  • ICU Cloud application with Microsoft to save PPE and Labor, monitor several ICU rooms at once by technology
  • Quadruple the production and enter new contracts, crisis exposed weaknesses in supply chain of many products
  • Shortage of PPE was not expected, flexibility and trusted relations with GE Health Suppliers
  • CT in a BOX – 42 Slices in a container – no exposure to radiation in prefabricated rooms in field hospital requiring no contact with clinicians and rapid response
  • Command control center with John Hopkins University
  • Manufacturing facilities in China communicate the situation of the business and the customers needs buyers in the Health care industry
  • Future for Biotech industry: Modular systems deploy rapidly, test vaccine, SPEED is everything productivity & Speed
  • Productivity will increase collaboration and speed like partnership with FORD and MIcrosoft

Add Panel to Calendar

11:45 AM – 12:10 PM
Big Tech and Digital Health

Tech giants are dedicating their vast resources to aid in the global response to the coronavirus. This panel will highlight how the big data and computational power of major tech companies is being deployed to help contain the current pandemic through new technologies and services, enable return to work, and how it could help prevent future ones.

Moderator:
Natasha Singer, Reporter, New York Times

Amanda Goltz, Principal, Business Development, Alexa Health & Wellness, Amazon

Michael Mina, MD, PhD, Associate Medical Director, Molecular Virology, BH; Assistant Professor, Epidemiology, Immunology and Infectious Diseases, Harvard Chan School

  • Limitations on Viral Testing
  • Shortage of Swabs for testing
  • Tech giant: Amazon, Walmart – global reach in supply chain
  • new collaborations formed on super charge
  • Antigen test for home administration consumerization of the Testing
  • Walmart can be positioned for blood tests
  • Not only Physicians can order tests
  • Microsoft and Amazon can help in interpretation of the Test using Alexa

Marcus Osborne, VP, Walmart Health, Walmart

Jim Weinstein, MD, SVP, Microsoft

Add Panel to Calendar

12:10 – 12:35 PM
LUNCH BREAK
12:35 – 12:55PM
FIRESIDE CHAT
Insights on Pandemics and Health Care from the National Security Community

General Alexander, a renowned expert on national security as well as pandemics and health care, will reflect on how AI can help identify and predict future global disease outbreaks and enable fully reopening commerce. He will also discuss what health care systems can learn from the response to COVID-19 to ensure preparedness for the next infectious disease challenge.

Moderator:
Gregg Meyer, MD, Chief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor of Medicine, HMS

General (Ret) Keith Alexander, Co-CEO, IronNet Cybersecurity

Add Panel to Calendar

12:55 – 1:20 PM
Calibrating Innovation Opportunity and Urgency: Medical and Social

The social and medical needs of patients are deeply intertwined, yet there are significant gaps in the tools and technologies being developed to help address those needs. These are especially apparent in the non-uniform impact of COVID-19. Harnessing opportunities, particularly for patients whose needs fall into the low medical complexity/high social complexity category — a group often overlooked by health care innovators.

Moderator:
Natasha Singer, Reporter, New York Times

Giles Boland, MD, Chair, Department of Radiology, BH; Philip H. Cook Professor of Radiology, HMS

  • Boston Hope: 1400 patients were treated at Boston Convention Center, 700 COVID -19 patients and 700 post acute after release from ICUs
  • Policy makers to address social determinants of Health

Amit Phadnis, Chief Digital Officer and GE Company Officer, GE Healthcare

  • Crisis will go away the innovations will stay and develop
  • Population Health to benefit from iPhone in Africa and in India mapping hotspots in populations
  • Multi channels TV, Phones and other devices – social disparities – no app to address social inequality

Krishna Yeshwant, MD, General Partner, GV; Instructor in Medicine, BH

  • communities most affected by social determinants of Health like in Chelsea in MA, a hotspot for COVID-19
  • Google Ventures – social issues are most complex invest in underprivileged

Add Panel to Calendar

1:20 – 1:45 PM
FDA Role in Managing Crisis and Anticipating the Next

The FDA and other regulatory bodies have played a key role in managing the coronavirus pandemic. How will the agency’s priorities shift in the coming months as community transmission (ideally) slows? What is the FDA’s role in return to work? What is the FDA doing to anticipate future health crises? How will these drive new tools and effect that rate of innovation?

Moderator:
Ravi Thadhani, MD, CAO, Mass General Brigham; Professor of Medicine and Faculty Dean for Academic Programs, HMS

Amy Abernethy, MD, PhD, Principal Deputy Commissioner & Acting CIO, FDA

  • Future – common tools, more efficient studies study protocols and study design evaluation
  • Learned what need to be put in place to move fast learn what is not in place
  • post pandemic regulatories lessons for being ready for the next one

Lindsey Baden, MD, Director, Clinical Research, Division of Infectious Diseases, BH; Associate Professor, HMS

  • Identify diagnostics for clinical definition of a virus unknown
  • treatment to be developed
  • Sick patients in need for treatment, researchers and clinicians need the best available FDA and the hospitals are flexible in responding
  • Spread globally like a respiratory virus
  • IRB – fast than ever before FDA and Pharma, DSMB – speed

Add Panel to Calendar

1:45– 2:05 PM
FIRESIDE CHAT
Keeping Priority on the Biggest Diseases

Biogen CEO Michel Vounatsos will discuss how Biogen is tackling some of society’s most devastating neurological and neurodegenerative disorders, and share his perspective on the impact the global COVID-19 pandemic is having on the biopharmaceutical industry.

Moderator:
Jean-François Formela, MD, Partner, Atlas Venture

  • Testing programs – lack of government cooordination

Michel Vounatsos, CEO, Biogen

  • Venture community supportive
  • to be on the safe side
  • employees tested every evenings to prevent rebound of the pandemic
  • Pandemic is acceleration progress that was only dreamt about
  • Opportunities in technologies new drugs,
  • Biogen will lead the new model
  • ALS – rare genetic expression Phase I encouraging
  • Neuro-immunology – MS phase III Parkinson drug
  • Lessons from COVID-19: Delay in clinical trials because Patients are fearing Hospital admission – Stroke patient did not go to Hospital
  • Biogen is joining the fight against COVID
  • Neuroimmunology is the strength – remain focus

 

Add Panel to Calendar

2:05 – 2:30 PM
Building the Plane While Flying: The Experience of Real-Time Innovation from the Front Line

The COVID-19 crisis has required continuous, real time innovation, impacting the way care is delivered on the front lines and across care continuum. This panel will present the perspective, innovations and experiences of care givers interacting directly with patients across the continuum of care – acute, post-acute, rehab and home care.

Moderator:
Ann Prestipino, SVP; Incident Commander, MGH; Teaching Associate, HMS

  • coming out of crisis
  • the New normal will be diferent

Theresa Gallivan, RN, Associate Chief Nurse, MGH

  • Ambulatory procedures
  • 700 nurses were deployed
  • 164 ICU beds increase of 90%
  • Health care demand will change in the future
  • focussed problem alarms from ventilators were not coordinated till biomed engineers arrives to device a solution

 

Karen Reilly, DNP, RN, Associate Chief Nursing Officer, Critical Care, Cardiovascular and Surgical Services, BH

  • Collaborate and move forward
  • Interdisciplinary team: Physical therapy help quickly
  • tech to communicate with families
  • Ready – I wish I had information to stay ahead of the curve
  • New normal ability to expand and contract

Ross Zafonte, DO, SVP, Research Education and Medical Affairs, SRN; Earle P. and Ida S. Charlton Professor of Physical Medicine and Rehabilitation, HMS

  • Rehabilitation in Cambridge Spaulding Brighton
  • Off loading to rehab from other units
  • Flexibility MGH Brigham – learn to be a new organization
  • Hotspots optimal mapping
  • Right person at right challenge
  • Stay ready for catastrophies
  • Telecare and Tele rehabilitation – greater benefit on TeleHealth or not who will not benefit from Rehab

Add Panel to Calendar

2:30 – 2:55 PM
CEO Roundtable: Will the Innovation Model Remain as It Was

As we envision a post-COVID-19 world, how will the model for biomedical innovation change? What lessons have been learned? Was this pandemic a once-in-a-lifetime event or should organizations begin to weave pandemic planning into their business and operations strategies? Panelists will discuss these and other related questions.

Moderator:
Janet Wu, Bloomberg

Mike Mahoney, CEO, Boston Scientific

  • China 6% of Sales
  • Employees – 148 Counties
  • support hospitals – 57% of volume
  • Resilience for liquidity Variable cost needed be removes partially
  • How will the company come out stronger
  • Innovations by business model innovations – Remote physicians in Japan by European experts in OR
  • Next week 10% of Product management and Quality are priority to come back
  • working remotely works very well except for R&S who needs Labs

Bernd Montag, PhD, CEO, Siemens Healthineers

  • Keep present business and the emerging needs for technologies
  • Serology Test
  • Antibody Test genomic testing
  • Company is Global but Health care is local

Add Panel to Calendar

2:55 – 3:05 PM
BREAK
3:05 – 3:30 PM
Emergency and Urgent Care: How COVID-19 Vulnerabilities and Solutions Will Change the Model

How are the roles of emergency medicine and urgent care changing in light of the COVID-19 pandemic? Panelists will discuss this topic as well as how current and anticipated new technologies can aid in the delivery of community, urgent, and emergency care now and in the future.

Given a false negative at the point of care has consequences well beyond the patient being treated, does this change what can be offered in the various patient care settings?

Moderator:
Ron Walls, MD, EVP and Chief Operating Officer, BH; Neskey Family Professor of Emergency Medicine, HMS

Troyen Brennan, MD, EVP and CMO, CVS Health

  • Labs – Quest Diagnostics
  • Point of care – Tests will move to Home will replace Labs
  • Pandemic heated hard people of color and comorbidities

David Brown, MD, Chair, Department of Emergency Medicine, MGH; MGH Trustees Professor of Emergency Medicine, HMS

  • Tele Urgent care
  • EMS Providers using TeleHealth
  • Scaled up capability needed administered by Governmental agency
  • new surges of some disease after Re-opening
  • Sensitivity of test for ill patient
  • Demand for Urgent Care will decline higher acuity will increase

Julie Lankiewicz, Head, Clinical Affairs & Health Economics Outcomes Research, Bose Health

  • Management of care with VRE other microbial agents
  • Vulnerable populations EKG between patients no more
  • mitigation of care – Brand new prescriptions for Anxiety and burnout
  • Digital solution to replace medications – audio content to avoid pharmacology by other methods of relaxation
  • Herd immunity  – Digital transformation

Michael VanRooyen, MD, Chairman, Department of Emergency Medicine, BH; Director, Humanitarian Initiative, Harvard University; Professor, HMS

  •  Separate Patients from Providers
  • Infection threat – Intubation – Tent for airsolize – trap air in the hood
  • manage Emergence Health OUT side of EM at Hospital
  • Rapid testing will continue to be central in Emergency Care

Add Panel to Calendar

3:30 – 3:55 PM
Accelerating Diagnostics – Maintaining the Priority: Lab, Home and Digital

COVID-19 diagnostics, a linchpin in controlling viral spread — what caused testing in the U.S. to fall so far behind and how can those missteps be prevented in the future? How do the diagnostics industry, and academic medicine, develop the tests that enable group activities including businesses sports, and community? What is the profile of diagnostic tests coming online in the coming months and into next year? What lessons can be learned to guide the global health community in future disease outbreaks? Given the biological complexity, required performance standards, and immense volume is a simple DTC assays possible on a greatly accelerated timeline.

Moderator:
Jeffrey Golden, MD, Chair, Department of Pathology, BH; Ramzi S. Cotran Professor of Pathology, HMS

James Brink, MD, Chief, Department of Radiology, MGH; Juan M. Taveras Professor of Radiology, HMS

  • social determinant of care – communities not able to social distance, multiple languages
  • Radiology: Rapid evolution of pandemic
  • MGB – Standardizations

John Iafrate, MD, PhD, Vice Chair, Academic Affairs, MGH; Professor, Pathology, HMS

  • Ability for Rapid testing was not in existence in the US
  • CDC Test deployed
  • BD and Roche diagnostics will
  • recipients and donors of antibodies

Celine Roger-Dalbert, VP Diagnostic Assays R&D – Integrated Diagnostic Solutions, BD Life Sciences

  • Telemedicine collection of samples outside the hospital
  • Testing if a patient had – serology – antibody – past exposure after day 14
  • Testing if a patient has – PCR after 10 days the virus is not infectious but it is present
  • antigen detection testing
  • molecular test

Matt Sause, President and CEO, Roche Diagnostics Corporation

  • Serology – more people become infected
  • active infection
  • Partnership between FDA and the manufactures
  • In the US scaling – infrastructure in place is a must

 

Add Panel to Calendar

3:55 – 4:15 PM
FIRESIDE CHAT
Return to Work: Understanding the Technologies and Strategies

Diagnostic testing is a linchpin of the worldwide response to the coronavirus. How does a global leader pivot to develop molecular diagnostics for a novel global pathogen? How does it scale, including managing international supply chains, to provide unprecedented levels of products and services. What are the expectations for return to work and a possible disease spike in fall 2020 or beyond. How will the diagnostics industry be permanently changed.

Moderator:
Peter Markell, EVP, Finance and Administration, CFO & Treasurer, Mass General Brigham

Marc Casper, Chairman, President and CEO, Thermo Fisher Scientific

  • Re-opening the economy requires Testing for certification of health
  • Testing bringing confidence
  • PCR – have or have not viral proteins: 5Millions a week, June 10 million tests
  • antibody testing will also become available in massive scale
  • Supply chain, more preparedness, robustness of the supply chain
  • Buying supply in China vs US based
  • stockpiling by governments not only at the Hospital level vs JIT shocks to the system
  • Work from home – productivity is good, work from home not ideal environment
  • Transportation and elevators – social distancing – impossible
  • Global change enormous Telemedicine ramp up Academic center Telemedicine will prevail
  • more resilient Health care system dialogue and communications across countries technology will play a role it will improve Health care every where

Add Panel to Calendar

4:15 – 4:40 PM
Digital Therapeutics: Current and Future Opportunities

Digital therapeutics (DTx) represents an emerging class of therapies that is poised for significant growth. Yet already, these software-driven, evidence-based tools for the prevention, management, and/or treatment of disease are already changing patients’ lives. This panel will address how existing DTx are having an early impact — in the COVID-19 pandemic and — and where current development efforts are headed in the coming years especially if there is a aggressive return of the virus in the fall 2020 or later.

Moderator:
Hadine Joffe, MD, Vice Chair for Research, Department of Psychiatry, Executive Director, Mary Horrigan Connors Center for Women’s Health and Gender Biology, BH; Paula A. Johnson Professor, Women’s Health, HMS

Priya Abani, CEO, AliveCor

  • Medical grade EKG devices
  • Telemedicine on the rise

Julia Hu, CEO, Lark Health

  • AI 24×7 counseling data streaming in data
  • TeleHealth
  • VirtualHealth Provider – working hard to scale
  • Patients @Home work at their schedule 9PM – midnight text messaging
  • 70% in employment reported stress experienced by employees

Dawn Sugarman, PhD, Assistant Psychologist, Division of Alcohol, Drugs, and Addiction, McLean; Assistant Professor, Psychiatry, HMS

  • Opioid & substance abuse
  • Treatment gap for women – gender specific Programs online gender specific  treatment

Add Panel to Calendar

4:40 – 5:05 PM
Investing During and After the Coronavirus Crisis

The investment environment in life sciences and health care overall was at record levels for most of the last decade. What will this environment look like in the wake of the COVID-19 pandemic – especially over the near to mid-term? Will investor priorities and enthusiasm shift? What is the investor role in developing new coronavisurs tests, vaccines, and therapeutics?

Moderator:
Roger Kitterman, VP, Venture and Managing Partner, Partners Innovation Fund, Mass General Brigham

Jan Garfinkle, Founder & Manager Partner, Arboretum Ventures

  • Can you close a deal with out meeting management team
  • Known funds will prevail vs new funds Parma adjacencies vs medical devices
  • Telehealth is of interest GI, Cardiovascular
  • Mental health with TeleHealth

Phillip Gross, Managing Director, Adage Capital Management

  • Clinical Trial issues
  • Inflating value of Biotech because therapeutic related to COVID gives a boost
  • 90 programs in clinical trials on Vaccine

Christopher Viehbacher, Managing Partner, Gurnet Point Capital

  • Health care was great investment because prople will get sick.
  • deal making switch to zoom meeting, no site visit, banking is adapting
  • relationship with people you do not know will be very hard
  • early stage if the cloud exist
  • Medical profession: Healthcare system is hurting revenue loss new technologies
  • clinical trials will be changing like for COVID
  • Sharing data will accelerate science

Add Panel to Calendar

5:05 – 5:10 PM
Closing Remarks
Gregg Meyer, MDChief Clinical Officer, Mass General Brigham; Interim President, NWH; Professor of Medicine, HMS
Ravi Thadhani, MD, CAO, Mass General Brigham; Professor of Medicine and Faculty Dean for Academic Programs, HMS

Mass General Brigham (formerly Partners Healthcare) is pleased to invite media to attend the World Medical Innovation Forum (WMIF) virtual event on Monday, May 11. Our day-long interactive web event features expert discussions of COVID-related infectious disease innovation and the pandemic’s impact on transforming medicine, plus insights on how care may be radically transformed post-COVID. The agenda features nearly 70 executive speakers from the healthcare industry, venture, start-ups, consumer health and the front lines of COVID care, including many of our Harvard Medical School-affiliated researchers and clinicians. The event replaces our annual in-person conference, which we plan to resume in 2021.

Read Full Post »


Worldwide trial uses AI to quickly identify ideal Covid-19 treatments

Reporter : Irina Robu, PhD

The novel coronavirus, SARS-CoV-2 that has been spreading around the world can cause a respiratory illness that can be severe. The disease, COVID-19 appears to have a fatality rate of less than 2 percent and forcing doctors to choose between two equally revolting options: try an unproven therapy and anticipate that it works or treat patients with standard supportive care for severe respiratory disease until a vaccine is developed.

Currently, randomized controlled trials have started in dozens of hospitals around the world by fusing two approaches together, using artificial intelligence to home in or using the most effective treatments for respiratory infections. The randomized trials, also known as an adaptive trial, in which scientists adjust the treatment protocols and/or statistical procedures based on the outcomes of participants. The trials are seen as a way to detect promising treatments and brand trials more flexible than traditional randomized trials and force patients, trial sponsors to wait for an outcome that often turns out to be disappointing. The inadequacies of the randomized approach have been taken into sharp relief during the pandemic, as thousands of patients can’t wait for gold-standard science to play out as they lay dying in intensive care of units.

However, analyzing data from more than 50 hospitals, researchers hope to supply quick answers to pressing questions such as the fact that the antimalarial drug hydroxychloroquine is an effective therapy and, if so, for which types of patients. The trial will also allow the researchers to test multiple therapies at once. Since the approach seems reasonable to give answers during a pandemic, it still has a lot of challenges, plus the necessity to rapidly assemble and analyze data from several hospitals with various record-keeping systems on three continents. Then update the protocols in accord during a crisis that is draining clinical resources.

Since several treatments are being tested, carrying out these trials is predominantly complicated. But progress in computing resources required to share data and analyze it swiftly using artificial intelligence have started to make these designs more practical.

The World Health Organization and the U.S. Food and Drug Administration, along with groups like the Gates Foundation, have offered increasing support for adaptive trial designs in recent years, particularly as a way to evaluate therapies during epidemics.

Nonetheless that doesn’t mean this specific effort is going to yield results in time to save the first wave of extremely ill patients. Once a promising treatment is recognized more patients will be allocated to receive it during each successive round of therapy. So far, about 130 ICU patients with Covid-19 have been enrolled, furthermore to hundreds of other hospitalized patients.

The goal in the REMAP-CAP trial, once all the trial sites are up and running, is to analyze results and change treatments on a weekly basis.

SOURCE

International trial uses AI to rapidly identify optimal Covid-19 treatments

Other Resources

Chinese Hospitals Deploy AI to Help Diagnose Covid-19

Software that reads CT lung scans had been used primarily to detect cancer. Now it’s retooled to look for signs of pneumonia caused by coronavirus.

https://www.wired.com/story/chinese-hospitals-deploy-ai-help-diagnose-covid-19/

 

Artificial Intelligence against COVID-19: An Early Review

AI has not yet made an impact, but data scientists have taken up the challenge

https://towardsdatascience.com/artificial-intelligence-against-covid-19-an-early-review-92a8360edaba

 

Can AI Find a Cure for COVID-19?

Alex Woodie

https://www.datanami.com/2020/03/23/can-ai-find-a-cure-for-covid-19/

 

Scientists are racing to find the best drugs to treat COVID-19

The WHO is launching a multicountry trial to collect good data

By Nicole Wetsman Mar 23, 2020, 9:21am EDT

https://www.theverge.com/2020/3/23/21188167/coronavirus-treatment-clinical-trials-drugs-remdesivir-chloroquine-covid

 

Data Scientists Use Machine Learning to Discover COVID-19 Treatments

Researchers are using machine learning algorithms capable of generating millions of therapeutic antibodies to quickly find treatments for COVID-19.

https://healthitanalytics.com/news/data-scientists-use-machine-learning-to-discover-covid-19-treatments

Read Full Post »


Tweets and Retweets @ COVID-19 and AI: A Virtual Conference – Human-Centered Artificial Intelligence Institute, Stanford University, 4/1/2020, 9AM PST – 3:30PM PST @StanfordHA